Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Another breakout is imminent
Still ver very cheap
Time to load up before the next jump coming
Anik is still one of the best and undervalued Bio stocks out there .Still a huge buying opportunity . glta
RALLLYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYY
Load up the truck before it moves over 20$ . Anik awaiting 6 Approvals ENUFF said .
RALLLYYYYYYYYYYYYYYYYYYYYYYYYY
Load up before its too late ..Easy mony from here .GL
Anik is a big buying opportunity . Load up on the cheap while you still can . GL
There is really a lot of good news coming ..Anik will explode today !
Great Fourth Quarter Results
http://phx.corporate-ir.net/External.File?item=UGFyZW50SUQ9Mzc0MzM4M3xDaGlsZElEPTQxNzQyMXxUeXBlPTI=&t=1
ANIK exploding after hour
Great results out .. Still a huge opportunity .GL
Still a huge buying opportunity ..
5 Approvals pending
GREAT BUYING OPPORTUNITY TODAY
LOAD UP WHILE ITS VERY CHEAP
Major Rally coming if we break 10$
2011 Price Target: $30.00+
UPCOMING MILESTONES :
Monovisc (osteoarthritis) (PMA) FDA approval in 1Q or early 2Q 2011 << Blockbuster Potential
Hyaloglide 510(K) expected FDA approval 1Q or early 2Q 2011
Hyalonect 510(K) expected FDA approval 1Q or early 2Q 2011
Hyalofast 510(K) expected FDA approval 1Q or early 2Q 2011
FAB has commercialized three joint health products that Anika is planning to market in the United States along with MONOVISC™, upon its approval by the FDA. These FAB products include:
* Hyaloglide®, a gel used following tendon and/or peripheral nerve surgery;
* Hyalonect®, a knitted mesh used as a bone graft wrap; and
* Hyalofast™, a non woven matrix of HA used in arthroscopic surgery for the repair of chondral and osteochondral lesions.
We believe these products will only require FDA 510K clearance. These three products – as well as most others in FAB’s portfolio – come with a meaningful clinical data package.
Our goal is to obtain FDA clearance for Hyaloglide, Hyalonect and Hyalofast by the end of Q1 2011. We are building a direct sales force to market MONOVISC in the United States, and adding these three products to our portfolio should provide us with the critical mass we need to more effectively penetrate the domestic orthopedic/joint health market.
what do you see this going to
Anik will explode if we break 10$ today
Still a huge buying opportunity .
Anik is on the move ...
Major Rally coming if we break $10 today .Still a fantastic buying opportunity .
Runup started
5 Approvals coming soon
The Institutions increased their stake in Anika from 30% to 51% in the last few days .VERY POSITIVE SIGN
http://www.dailyfinance.com/company/anika-therapeutics-inc/anik/nas/institutional-ownership
Shares Outstanding: 13.4 M
Insiders/Mutual/Institutions holding : 8.4 M
Float : 5 M (excluding retail investors)
This is the perfect buying time
Big News is around the corner
Good day to load up more cheap shares .
RALLLYYYYYYYYYYYYYYYYYYYYYYY
10$++++ coming yipppiiii
Last chance to get in below 9$ .
Anika Therapeutics (ANIK)
Market-Cap: 116 Mil
Cash: 26 Mil
Price: 8.60
Shares Out: 13.5
UPCOMING MILESTONES :
Monovisc (osteoarthritis) (PMA) FDA approval in 1Q 2011 << Blockbuster Potential
Hyaloglide 510(K) expected FDA approval 1Q 2011
Hyalonect 510(K) expected FDA approval 1Q 2011
Hyalofast 510(K) expected FDA approval 1Q 2011
FAB has commercialized three joint health products that Anika is planning to market in the United States along with MONOVISC™, upon its approval by the FDA. These FAB products include:
* Hyaloglide®, a gel used following tendon and/or peripheral nerve surgery;
* Hyalonect®, a knitted mesh used as a bone graft wrap; and
* Hyalofast™, a non woven matrix of HA used in arthroscopic surgery for the repair of chondral and osteochondral lesions.
We believe these products will only require FDA 510K clearance. These three products – as well as most others in FAB’s portfolio – come with a meaningful clinical data package.
Our goal is to obtain FDA clearance for Hyaloglide, Hyalonect and Hyalofast by the end of Q1 2011. We are building a direct sales force to market MONOVISC in the United States, and adding these three products to our portfolio should provide us with the critical mass we need to more effectively penetrate the domestic orthopedic/joint health market.
GREAT BUYING OPPORTUNITY TODAY FOLKS
4 FDA APPROVALS COMING VERY SOON = EASY $$$$
Load up before the first FDA approval coming ....
Anika Therapeutics (ANIK)
Market-Cap: 116 Mil
Cash: 26 Mil
Price: 8.60
Shares Out: 13.5
UPCOMING MILESTONES :
Monovisc (osteoarthritis) (PMA) FDA approval in 1Q 2011 << Blockbuster Potential
Hyaloglide 510(K) expected FDA approval 1Q 2011
Hyalonect 510(K) expected FDA approval 1Q 2011
Hyalofast 510(K) expected FDA approval 1Q 2011
FAB has commercialized three joint health products that Anika is planning to market in the United States along with MONOVISC™, upon its approval by the FDA. These FAB products include:
* Hyaloglide®, a gel used following tendon and/or peripheral nerve surgery;
* Hyalonect®, a knitted mesh used as a bone graft wrap; and
* Hyalofast™, a non woven matrix of HA used in arthroscopic surgery for the repair of chondral and osteochondral lesions.
We believe these products will only require FDA 510K clearance. These three products – as well as most others in FAB’s portfolio – come with a meaningful clinical data package.
Our goal is to obtain FDA clearance for Hyaloglide, Hyalonect and Hyalofast by the end of Q1 2011. We are building a direct sales force to market MONOVISC in the United States, and adding these three products to our portfolio should provide us with the critical mass we need to more effectively penetrate the domestic orthopedic/joint health market.
pull back is a great buying opportunity .
4 FDA approvals coming to push this stock to ath
If we break 10$ today then it will run to 15$ quickly .
Load up folks
Major Breakout coming ..
RALLYYYYYYYYYYYYYYYYYYYYYYY
Last chance to load up below 10$ .
4 FDA APPROVALS COMING TO PUSH THIS STOCK TO 30$ ..
Nice consolidation
Rally will continue very soon ..
Great buying opportunity today ..Load up before the big News is out .
This stock is still significantly Undervalued . Anik awaiting 4 FDA approvals including one potential Blockbuster(Monovisc) , the first Approval could push this stock to $15+ .I think we could see $30+ with all FDA approvals . Anika is definitely one of the best Biotech Investment .GL
http://stockcharts.com/freecharts/gallery.html?anik
Load up before the stock moves into double digits .Anything below 12$ is a pure gift . GL
http://www.stoxline.com/quote.php?symbol=anik
Resistance1: 9.78
Resistance2: 11.42
Price and moving averages has closed above its Short term moving average. Short term moving average is currently above mid-term; AND above long term moving averages. From the relationship between price and moving averages; we can see that: This stock is BULLISH in short-term; and BULLISH in mid-long term.
4 FDA approvals this Q(Mcap 96 M) Hot Pick 2011
With a market value of $96 million, Anika Therapeutics (ANIK) is a hidden growth story in the biotech arena .ANIK has been profitable for each of the past seven years.
2011 Price Target: $25.00+ .Get in now before the stock gets Discovered .Buy with both hands now and you will make a lot of money with the upcoming FDA approvals .Anika is a once in a lifetime opportunity .GLTA
Anika Therapeutics (ANIK)
Market-Cap: 96 Mil
Cash: 26 Mil
Price: 7.20
Shares Out: 13.5
UPCOMING MILESTONES :
Monovisc (osteoarthritis) (PMA) FDA approval in 1Q 2011 << Blockbuster Potential
Hyaloglide 510(K) expected FDA approval 1Q 2011
Hyalonect 510(K) expected FDA approval 1Q 2011
Hyalofast 510(K) expected FDA approval 1Q 2011
Big Pipeline
http://www.anikatherapeutics.com/innovation/pipeline/index.html
Insider Ownership
http://www.dailyfinance.com/company/anika-therapeutics-inc/anik/nas/institutional-ownership
http://www.anikatherapeutics.com/innovation/spotlight/index.html
FAB has commercialized three joint health products that Anika is planning to market in the United States along with MONOVISC™, upon its approval by the FDA. These FAB products include:
* Hyaloglide®, a gel used following tendon and/or peripheral nerve surgery;
* Hyalonect®, a knitted mesh used as a bone graft wrap; and
* Hyalofast™, a non woven matrix of HA used in arthroscopic surgery for the repair of chondral and osteochondral lesions.
We believe these products will only require FDA 510K clearance. These three products – as well as most others in FAB’s portfolio – come with a meaningful clinical data package.
Our goal is to obtain FDA clearance for Hyaloglide, Hyalonect and Hyalofast by the end of Q1 2011. We are building a direct sales force to market MONOVISC in the United States, and adding these three products to our portfolio should provide us with the critical mass we need to more effectively penetrate the domestic orthopedic/joint health market.
Followers
|
2
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
39
|
Created
|
02/03/11
|
Type
|
Free
|
Moderators |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |